What It Is
PE-22-28 is a research-stage synthetic peptide fragment discussed in the literature as an analog of spadin, a peptide originally identified from the propeptide of sortilin. Spadin itself was first described in 2010 as a blocker of the TREK-1 potassium channel with antidepressant-like effects in rodents, and PE-22-28 (also written PE 22-28) is a shortened variant studied in that same research lane.[1]
PE-22-28 is not a marketed or clinically established medication. It exists almost entirely within preclinical neuroscience research on ion-channel pharmacology and mood-related animal models, rather than as a characterized human therapeutic.[2]
How It Works
The proposed mechanism involves TREK-1, a two-pore-domain potassium channel encoded by the KCNK2 gene that helps set the resting excitability of neurons.[6] [7] Spadin, and by extension shortened analogs such as PE-22-28, are studied as TREK-1 blockers. In mice, genetically deleting TREK-1 produces a depression-resistant behavioral phenotype, part of the reason researchers became interested in TREK-1 blockade as a route to antidepressant effects.[9]
Blocking a background potassium channel changes how easily neurons fire and can alter downstream neurotransmitter signaling, including serotonergic pathways implicated in mood regulation.[8] This is a coherent pharmacological hypothesis, but a channel-level mechanism demonstrated in rodents does not establish that PE-22-28 produces any clinical effect in humans.
What the Research Shows
Nearly all relevant evidence is preclinical and rodent-based. TREK-1 knockout mice and spadin-treated animals have shown antidepressant-like behavior in standard rodent screening tests, alongside mechanistic findings related to hippocampal neurogenesis pathways also studied in conventional antidepressant research.[9]
Under the specific name PE-22-28, public searches of PubMed and ClinicalTrials.gov do not identify a meaningful registered human trial record, and no published human efficacy or pharmacokinetic data exist under this name.[3] Claims about mood, memory, or brain-support benefits in people are therefore extrapolated from spadin/TREK-1 animal research rather than demonstrated directly for PE-22-28, and should be read as hypothesis, not established fact.
Safety & Side Effects
No human safety database exists for PE-22-28. Because it is proposed to act on a CNS potassium channel involved in neuronal excitability, plausible theoretical concerns include unpredictable effects on mood, sedation, and neurologic function, plus unknown interactions with antidepressants, mood stabilizers, or antiepileptic drugs.
People with bipolar disorder, epilepsy, or other seizure-related conditions, and anyone pregnant or breastfeeding, have essentially no relevant safety data to draw on. In the absence of human trials, an unremarkable safety record simply reflects that no one has systematically looked, not that the compound has been shown safe.
Regulatory Status
PE-22-28 does not appear as an approved medicine in FDA or EMA databases under this name, and it has no approved indication, labeled dose, or prescribing information anywhere.[4] [5] It is a research chemical, not a regulated pharmaceutical product.
Products marketed online as pharmaceutical-grade PE-22-28 are not FDA-reviewed for identity, purity, or sterility, since the FDA explicitly distinguishes compounded and unapproved drugs from products that have undergone its safety and efficacy review.[14] Anyone interested in PE-22-28 for a mood-related or cognitive concern should pursue evidence-based, approved treatment options through a licensed clinician rather than an unregulated research peptide.